Loading stock data…
STAAR Surgical Company (STAA)
$29.33+0.04 (+0.14%)
After Hours$29.33+0.00 (+0.00%)· Last close Jun 29
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
STAAR Surgical Company in the Healthcare sector is trading at $29.33 with a market capitalization of $1.4B. Wall Street consensus targets $29.67 (9 analysts), implying a +1.1% move over the next 12 months. The stock is currently 18% below its 52-week high of $35.87, remaining 20.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $93.52M↑ | $57.80M↓ | $94.73M↑ | $44.32M↑ | $42.59M |
| Gross Profit | $68.86M↑ | $43.74M↓ | $77.88M↑ | $32.80M↑ | $28.00M |
| Operating Income | $17.40M↑ | -$10.94M↓ | $24.44M↑ | -$24.72M↑ | -$34.74M |
| Net Income | $5.21M↑ | -$18.31M↓ | $8.88M↑ | -$16.81M↑ | -$54.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.97%
Volume
Today's trading volume
856,329
Recent News
1 Cash-Heavy Stock to Keep an Eye On and 2 We Ignore
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
1 Cash-Burning Stock to Keep an Eye On and 2 We Find Risky
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.
Medical Devices & Supplies - Specialty Stocks Q1 Earnings: STAAR Surgical (NASDAQ:STAA) Firing on All Cylinders
Let’s dig into the relative performance of STAAR Surgical (NASDAQ:STAA) and its peers as we unravel the now-completed Q1 medical devices & supplies - specialty earnings season.
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
How The STAAR Surgical (STAA) Story Is Shifting After Q1 And New Analyst Targets
STAAR Surgical’s modeled fair value has been updated from US$21.11 to US$29.67, a shift that puts a brighter spotlight on how analysts are recalibrating their expectations. That change sits alongside a mix of more optimistic and cautious views, with some firms lifting targets after a stronger Q1 and others still focused on patchy visibility, especially around China and future guidance. Read on to see what is driving the evolving narrative and how you can track it over time. Stay updated as...